LZAGF - Bristol-Myers Squibb Contingent Value Rights: Final Inspection Is Happening
- The contingent value right issued to Celgene shareholders after the Bristol-Myers acquisitions are dependent on approval of Liso-cell and Ide-cell.
- For Liso-cell to be approved the FDA seems insistent on inspection of a Texas-based Lonza facility.
- Twitter sources point toward a physical inspection having been initiated at the Lonza facility.
- At the same time the rights have been surging in value.
- In my view this is a highly positive development although it's still possible the contingent value rights will ultimately be worthless.
For further details see:
Bristol-Myers Squibb Contingent Value Rights: Final Inspection Is Happening